Given Imaging Announces Fourth Quarter 2002 Revenues of $9.0 Million

Revenues increase 157% over fourth quarter 2001

1/16/2003 - Yoqneam, Israel -- Given Imaging (NASDAQ: GIVN) announced today that worldwide sales of its Given® Diagnostic Imaging System and M2A video capsule reached $9.0 million in the fourth quarter of 2002. This represents a 157% increase over sales generated in the fourth quarter of 2001. Sales for the twelve months ended December 31, 2002 were $28.9 million.

"During 2002, we saw a growing number of peer review publications on capsule endoscopy as well as an expanding list of both public and private payers who reimburse patients for capsule endoscopy procedures. Both of these factors create an excellent base for future growth of Given Imaging," said Gavriel D. Meron, president and chief executive officer of Given Imaging.

Fourth Quarter Conference Call Details

Given Imaging expects to release its fourth quarter financial and full-year 2002 results on February 12, 2003. In conjunction with the release of earnings, the Company will host a conference call on February 13, 2003, 9:00 am EST, which will be broadcast live on Given Imaging’s web site at www.givenimaging.com.

This press release contains forward-looking statements about Given Imaging, including projections about our business, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03